drugset / Trial / NCT02998996

Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU

NCT02998996

Phase 1/2 Completed 162 enrolled Eurocine Vaccines AB
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The main purpose of the this study is to evaluate the safety and tolerability of Immunose™ FLU based on Endocine™ and quadrivalent influenza antigen.

Timeline

Start
2016-09
Primary completion
2017-06-01
Completion
2017-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza antigen Vaccine 15 ug Intranasal
Subject Vacc-4x Peptide 1 % Intranasal
Subject Vacc-4x Peptide 2 % Intranasal

Indications